In the BioHarmony Drug Report Database

"Preview" Icon

Teduglutide

Gattex, Revestive (teduglutide) is a protein pharmaceutical. Teduglutide was first approved as Gattex on 2012-08-30. It is used to treat short bowel syndrome in the USA. It has been approved in Europe to treat malabsorption syndromes. The pharmaceutical is active against glucagon-like peptide 2 receptor. Gattex’s patents are valid until 2025-11-01 (FDA).

 

Trade Name

 

Revestive
 

Common Name

 

teduglutide
 

ChEMBL ID

 

CHEMBL2104987
 

Indication

 

malabsorption syndromes, short bowel syndrome
 

Drug Class

 

Peptides: GLP peptide analogs

Image (chem structure or protein)

Teduglutide structure rendering